In the VCU-ART clinical study, treatment with anakinra reduced the incidence of new-onset HF and hospitalization for HF, whereas in the CANTOS trial, treatment with the IL-1β blocking antibody canakinumab significantly reduced the occurrence of recurrent cardiovascular events compared with a placebo [179–181]. This evidence concerns the gene IL1B and hydrops fetalis.